Welcome to ZisNews!

Read your favorite news, except the excluded topics, by you. Register
No overlapping ads for registered users

Painkillers, muscle relaxants among 16 more FDCs banned

Posted on: Jun 21, 2026 06:02 IST | Posted by: Hindustantimes
Painkillers, muscle relaxants among 16 more FDCs banned
THe unification ministry of wellness and fellowship welfare has prohibited 16 thomas more fixed dose combinations (FDC), including skin medications, painkillers and muscle relaxants, that it felt had limited therapeutic use, according to people familiar with the matter.“The health ministry has issued notifications under Section 26A of the Drugs and Cosmetics Act, 1940, prohibiting the manufacture for sale, sale and distribution for human use of 16 FDCs. The notifications have come into force with immediate effect,” read the health ministry statement.FDC drugs are those that contain a combination of two or more active pharmaceutical ingredients in a fixed ratio and are also referred to as “cocktail” drugs.According to the health ministry, the decision followed directions of the Supreme Court, which mandated a comprehensive review of FDCs available in the country. In compliance with these directions, the Drugs Technical Advisory Board (DTAB) constituted an expert committee to examine various FDCs and identify those that are “irrational, lack therapeutic justification or may pose risks to human health.”“Based on the scientific assessment and recommendations of the expert committee, the government has taken action against 16 FDCs that were found to lack therapeutic justification and whose continued use was not considered beneficial in relation to the potential risks involved,” read the health ministry statementThe prohibited FDCs belong to various therapeutic categories, including certain dermatological preparations, analgesic and antispasmodic medicines and antibiotic-based formulations.Among the FDCs banned are the combinations of aloe extract, allantoin , alphatocopherol acetate, D-penthenol and vitamin A; aloe extract, vitamin E, dimethicone and glycerine; aloe vera , jojoba oil, wheat germ oil and tea tree oil; dicyclomine, paracetamol and clidinium bromide; dicyclomine, paracetamol and clidinium bromide; paracetamol and lignocaine; amoxicillin, serratiopeptidase and lactobacillus sporogenes; amoxicillin, cloxacillin, lactic acid bacillus and serratiopeptidase; cefadroxyl and probenecid; cefuroxime and Serratiopeptidase.“The ministry noted that this action is in line with the government’s continuing efforts to ensure that only safe, effective and scientifically validated medicines are available to the public. In previous instances as well, several irrational FDCs were prohibited following detailed scientific review, reinforcing the commitment of the government towards patient safety and evidence-based healthcare,” read the health ministry statement.“Accordingly, the manufacture, sale, distribution and supply of the identified 16 FDCs for human use shall stand prohibited with immediate effect across the country,” the statement read.All state drug controllers, regulatory authorities and enforcement agencies have been directed to ensure strict implementation and compliance with the notifications. Manufacturers, importers, distributors and other stakeholders have also been advised to take necessary corrective measures to comply with the provisions of the law.The government in 2016 announced ban on 344 FDCs after an expert panel’s recommendations.Between 2023 and 2025, a total of 205 FDCs have been banned as part of the exercise to phase out unapproved fixed dose combination drugs from Indian market. Many of the FDCs banned over the years were also from those 344 drug combinations.

Global News Perspectives

In today's interconnected world, staying informed about global events is more important than ever. ZisNews provides news coverage from multiple countries, allowing you to compare how different regions report on the same stories. This unique approach helps you gain a broader and more balanced understanding of international affairs. Whether it's politics, business, technology, or cultural trends, ZisNews ensures that you get a well-rounded perspective rather than a one-sided view. Expand your knowledge and see how global narratives unfold from different angles.

Customizable News Feed

At ZisNews, we understand that not every news story interests everyone. That's why we offer a customizable news feed, allowing you to control what you see. By adding keywords, you can filter out unwanted news, blocking articles that contain specific words in their titles or descriptions. This feature enables you to create a personalized experience where you only receive content that aligns with your interests. Register today to take full advantage of this functionality and enjoy a distraction-free news feed.

Like or Comment on News

Stay engaged with the news by interacting with stories that matter to you. Like or dislike articles based on your opinion, and share your thoughts in the comments section. Join discussions, see what others are saying, and be a part of an informed community that values meaningful conversations.

Download the Android App

For a seamless news experience, download the ZisNews Android app. Get instant notifications based on your selected categories and stay updated on breaking news. The app also allows you to block unwanted news, ensuring that you only receive content that aligns with your preferences. Stay connected anytime, anywhere.

Diverse News Categories

With ZisNews, you can explore a wide range of topics, ensuring that you never miss important developments. From Technology and Science to Sports, Politics, and Entertainment, we bring you the latest updates from the world's most trusted sources. Whether you are interested in groundbreaking scientific discoveries, tech innovations, or major sports events, our platform keeps you updated in real-time. Our carefully curated news selection helps you stay ahead, providing accurate and relevant stories tailored to diverse interests.

Login to Like (0) Login to Dislike (0)

Login to comment.

No comments yet.